Is Vosoritide legal in the United Kingdom?

A C-type natriuretic peptide analogue approved for achondroplasia on a randomised phase 3. It increases growth velocity by roughly 1.6 cm a year, and nobody knows the effect on final adult height.

Vosoritide is the clearest example on this site of a peptide designed from a precise understanding of a single mutation. Achondroplasia is caused by a gain-of-function mutation in FGFR3 that over-suppresses growth plate cartilage.

Mechanism: A 39-amino-acid analogue of C-type natriuretic peptide, modified to resist degradation by neutral endopeptidase, which destroys the native peptide within minutes. It binds natriuretic peptide receptor B, raising cyclic GMP and activating protein kinase G, which inhibits the RAF and MEK and ERK cascade at the level of RAF-1.

Regulatory history: FDA-approved as Voxzogo to increase linear growth in children with achondroplasia with open epiphyses. Approval rests on growth velocity, not final adult height.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Vosoritide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.